Editor's Summary

Performance Enhancement

The stress response can help raise a person’s performance level at crucial times—when meeting a cougar on a hike, dancing Swan Lake for the first time, or teaching your teen to drive. But chronic stress strains the body and mind in unhealthy ways. This principle holds true at the molecular level. When organs place a high demand on the cell’s endoplasmic reticulum (ER) for proper synthesis, folding, and trafficking of large amounts of protein, misfolded or unfolded proteins can accumulate in the ER and trigger the unfolded protein response (UPR). The UPR is a complex program that drives either proper folding of misfolded proteins via chaperones or degradation of these proteins to restore ER homeostasis. This adaptation to ER stress is beneficial in acute situations but detrimental under chronic pathological conditions. Indeed, recent research illustrates the importance of restoring ER homeostasis in type 2 diabetes (T2D) and neurodegenerative disorders. Now, Engin et al. investigate ER stress in the context of autoimmune (type 1) diabetes (T1D).

Tweaks in ER homeostasis are known to spur stress responses that modify glucose and lipid metabolism. But little is known about the role of the UPR in the natural history of T1D or in the disease’s characteristic dysfunction and death of pancreatic β cells. These cells play a central role in initiating carbohydrate metabolism by secreting insulin in response to glucose intake.

The authors uncovered defects in the expression of two UPR mediators, ATF6 (activating transcription factor 6) and XBP1 (X-box binding protein 1), in pancreatic β cells from T1D patients and two distinct mouse models of T1D. When the mice were treated at the prediabetic stage with tauroursodeoxycholic acid (TUDCA) —a bile acid produced by the liver and known to quell ER stress —diabetes incidence was significantly reduced in an ATF6-dependent manner. The treated mice also displayed decreased infiltration of autoimmune-associated lymphocytes in the pancreas and increased survival, insulin secretion, and UPR-mediator expression in pancreatic β cells.

The data show that, in mouse models of T1D, a functional UPR participates in the preservation of pancreatic β cells and that UPR dysfunction can be prevented with TUDCA therapy. Currently, autoantibody testing permits the identification of human T1D patients one to two years before they develop symptoms. Therefore, this study suggests a strategy for preventing aberrant ER function in prediabetic autoantibody-positive patients. Further, a clinical (safety) trial for the TUDCA precursor UDCA was initiated for patients with Huntington’s disease (NCT00514774), a neurological disorder that is associated with protein misfolding and aggregation and might involve a dysfunctional UPR. Thus reversing stressful conditions in the ER might have wide-ranging therapeutic consequences.
Perturbations in endoplasmic reticulum (ER) homeostasis can evoke stress responses leading to aberrant glucose and lipid metabolism. ER dysfunction is linked to inflammatory disorders, but its role in the pathogenesis of autoimmune type 1 diabetes (T1D) remains unknown. We identified defects in the expression of unfolded protein response (UPR) mediators ATF6 (activating transcription factor 6) and XBP1 (X-box binding protein 1) in β cells from two different T1D mouse models and then demonstrated similar defects in pancreatic β cells from T1D patients. Administration of a chemical ER stress mitigator, tauroursodeoxycholic acid (TUDCA), at the prediabetic stage resulted in a marked reduction of diabetes incidence in the T1D mouse models. This reduction was accompanied by (i) a significant decrease in aggressive lymphocytic infiltration in the pancreas, (ii) improved survival and morphology of β cells, (iii) reduced β cell apoptosis, (iv) preserved insulin secretion, and (v) restored expression of UPR mediators. TUDCA’s actions were dependent on ATF6 and were lost in mice with β cell–specific deletion of ATF6. These data indicate that proper maintenance of the UPR is essential for the preservation of β cells and that defects in this process can be chemically restored for preventive or therapeutic interventions in T1D.

INTRODUCTION

Type 1 diabetes (T1D) results from the immune-mediated destruction of insulin-producing β cells in the hormone-generating islets of Langerhans in the pancreas. Loss of pancreatic β cells leads to a decrease in insulin production, unsuppressed glucose production, and hyperglycemia (1, 2). The prevalence of T1D in humans between the ages of 0 and 19 years was reported to be 1.7 per 1000 and has been rising globally and by as much as 5.3% annually in the United States (3). The initial signals that trigger autoimmunity and the intracellular mediators that lead to destruction of β cells in T1D remain poorly understood, a situation that hampers the development of targeted therapies for the disease. Growing experimental evidence suggests that dysregulation of the endoplasmic reticulum (ER) responses contributes to T1D pathogenesis through multiple potential mechanisms that eventually lead to β cell demise (2, 4–6). For example, acute and chronic stimulation of β cells by nutrients such as glucose, arginine, or lipids induces the production of large amounts of insulin, which places a continuous demand on the ER for proper protein synthesis, folding, trafficking, and secretion. When the folding capacity of the ER is exceeded, misfolded or unfolded proteins accumulate in the ER lumen, triggering the unfolded protein response (UPR). The UPR is an integrated response program that reduces translation, increases chaperone availability, and enhances the degradation of misfolded proteins in an attempt to restore ER homeostasis.

Although physiological stimulation of the UPR may be beneficial for β cell function and acute adaptation to stress, under pathological conditions severe or prolonged ER stress hinders β cell function and survival (7, 8). In experimental animal models and in humans, mutations in genes critical for ER function result in β cell failure and severe early-onset diabetes (9–17). In fact, misfolded insulin alone can cause diabetes in both mice and humans (18–23).

Proinflammatory cytokines produced by islet-infiltrating immune cells also lead to β cell destruction by direct cytotoxicity, inducing expression of FAS [tumor necrosis factor (TNF) receptor superfamily, member 6], and enhancement of immune recognition (4). Putative inflammatory mediators of β cell loss in T1D, such as interleukin-1β (IL-1β), TNF-α, and interferon-γ (IFN-γ), were all shown to induce ER stress through multiple mechanisms (24, 25), leading to the depletion of ER calcium, dysfunction of ER chaperones, and a severe disruption in ER homeostasis (26, 27). Hence, cytokine-induced alterations in ER function can affect cell adaptation and amplify proapoptotic pathways. Reciprocally, chronic ER stress can engage stress and inflammatory pathways through activation of c-Jun N-terminal kinase (JNK), inhibitor of nuclear factor κB kinase (IKK), and protein kinase R (PKR), and this low-grade chronic inflammation may also contribute to eventual islet destruction (6, 28, 29). Indicators of ER stress are present in inflamed islets of both diabetes-prone nonobese diabetic (NOD) mice (30) and patients with T1D (31).

Viral infection, environmental toxins, chronic inflammation, abnormal protein folding, and a surplus of nutrients all can cause ER stress and trigger the UPR (32). In addition to the prosurvival aspects of the UPR described above, when stress is prolonged and unresolved, the UPR can engage apoptotic pathways. The canonical UPR operates through inositol-requiring protein 1 (IRE1), protein kinase RNA-like ER kinase (PERK), and activating transcription factor 6 (ATF6), all of which are localized in the ER membrane and respond to stress by relaying signals from the ER to the cytoplasm and nucleus. Recent studies elucidated the importance of ER stress and the beneficial effects of restoring organelle function through chemical and lipid chaperones in...
the context of obesity, insulin resistance, type 2 diabetes (T2D), and atherosclerosis (33, 34).

Unlike T2D, however, it remains unclear whether ER stress and components of the UPR play a mechanistic role in the steps leading to pancreatic β cell dysfunction and death in T1D. Here, we investigated the role of the UPR and its components during the pathogenesis of T1D in mouse models and in human subjects. Furthermore, we explored the prospect of UPR-modulating chemical chaperones as potential therapeutic agents in the preservation of β cell function and survival in T1D.

RESULTS

To investigate whether an aberrant UPR plays a role during the natural course of T1D, we first examined the expression patterns of key UPR mediators, sXBP1 (spliced X-box binding protein 1) and ATF6, in pancreata of NOD mice at 3, 5, 7, 9, and 13 weeks of age (n = 14 for each group). For immunohistochemical analysis of the pancreatic islets, we used both commercially available and in-house antibodies against ATF6 and sXBP1, after validating their specificities by lack of staining in the pancreatic sections of mice with targeted null mutations in these genes (fig. S1, A and B). Expression of ATF6 in the β cells of the pancreatic islets of NOD mice showed a slight increase from 3 to 5 weeks of age; however, there was a sharp decline in ATF6 immunostaining of the islets starting at week 7, which became more pronounced at 13 weeks of age (Fig. 1, A and C). sXBP1 expression exhibited a somewhat different expression pattern compared with that of ATF6. It was detected at low levels at 3 weeks of age but showed a significant increase at 5 weeks of age (Fig. 1, B and D). sXBP1 expression started to decline during weeks 7 and 9, with the greatest decline observed at 13 weeks of age (Fig. 1B). Insulin staining intensity in these islets remained the same until 7 weeks, but showed a mild decrease at 9 and 13 weeks of age (Fig. 1E). Plasma insulin levels were also maintained through 7 weeks of age (Fig. 1F).

To examine alterations in the third branch of the UPR, we stained the same pancreatic sections with an antibody to phosphorylated eukaryotic translation initiation factor 2α (phospho-eIF2α), which indicates activation of PERK and subsequent attenuation of translational initiation. Although phospho-eIF2α staining was below detection in most β cells, islet non–β cells exhibited detectable signals (fig. S1C). Phospho-eIF2α staining markedly decreased at 5 weeks of age and then significantly increased at 7 weeks. Phospho-eIF2α staining through 9 and 13 weeks of age remained similar in β cells to the initial levels observed at 3 weeks of age (fig. S1, C and D). We also examined Glut2, the major glucose transport protein in murine β cells, and Keap1, a transcription factor that regulates antioxidant genes (35), as additional controls. Although Glut2 staining showed a clear increase in β cells already at 5 weeks of age, Keap1 immunostaining remained the same throughout the time course studied in NOD islets (fig. S2, A to D). These results indicate that the UPR is modulated during diabetes progression in the β cells of NOD mice and precedes the decline in β cell number and function and the emergence of frank diabetes, which is usually observed after 12 weeks of age.

To explore whether a defective UPR is a common phenomenon of T1D, we also examined the expression of UPR markers in the islets of an independent diabetic mouse model induced by viral infection (36). Similar to the observations in NOD mice, the expression of both ATF6 and sXBP1 was severely defective in the RIP-LCMV-GP (rat insulin promoter–lymphocytic choriomeningitis virus–glycoprotein) model preceding the onset of hyperglycemia (fig. S2, E and F). These data indicate that failure of the proresolusion functions of the UPR in T1D models is related to impaired functions of ATF6 and XBP1. Furthermore, these observations suggest that a disregulated UPR may contribute to the pathogenesis of immune-mediated diabetes in mouse models.

To evaluate the expression of UPR markers in human T1D patients, we obtained pancreatic sections from control (n = 6) and diabetic (n = 10) individuals [from the Network for Pancreatic Organ Donors with Diabetes (nPOD)] (Table 1) and performed immunofluorescence analysis of ER stress markers in these samples. These data also supported the presence of ER stress indicators in the initial stages of disease, which markedly declined later on (Fig. 2). When the data from all subjects were combined and quantitated, we observed significantly reduced ATF6 (Fig. 2, A and D) and sXBP1 (Fig. 2, B and E) staining intensity in insulin-positive β cells (Fig. 2C) of subjects with diabetes compared with healthy controls. The expression of insulin, ATF6, and sXBP1 was also quantified in controls and in patients individually grouped according to time of diagnosis (indicated by years) (fig. S3, A to C). Representative stainings are shown in female (Fig. 2, A and B) and male (fig. S3, D and E) control and diabetic subjects. This pattern of defective ATF6 and sXBP1 expression was more striking in female patients who had diabetes for 8 to 20 years than in male patients, whose staining pattern was milder but still present. Similar to what we have observed in animal models, these results demonstrate that the ATF6 and XBP1 branches of the UPR are down-regulated in β cells from subjects with diabetes, and thus that these pathways may be important for disease pathogenesis.

In experimental models of both T2D and atherosclerosis, chemical chaperones such as taurine-conjugated ursodeoxycholic acid (TUDCA) and phenyl butyric acid reduce ER stress and alleviate disease symptoms (34, 37, 38). These chemical chaperones also increase insulin sensitivity in obese and insulin-resistant subjects and provide protection against lipid-induced β cell dysfunction in humans (39, 40). We hypothesized that by increasing ER capacity, improving folding defects, or promoting the prosurvival or adaptive effects of the UPR, chemical chaperones might also protect pancreatic β cells in T1D. To test this hypothesis, we administered TUDCA to both NOD and RIP-LCMV-GP mice at 250 mg/kg twice daily via intraperitoneal injections for 20 and 2 weeks, respectively, and monitored body weight and blood glucose levels weekly. TUDCA treatment resulted in a striking reduction in diabetes incidence in both the NOD (44 versus 11%) (P < 0.05, Kaplan-Meier estimate) and RIP-LCMV-GP (100 versus 40%) (P < 0.05, χ² test) models (Fig. 3, A and B). To investigate the dose responsiveness of the TUDCA effect, we administered TUDCA (100, 50, and 25 mg/kg per day) to the RIP-LCMV-GP model and followed the diabetes incidence in these animals by measuring blood glucose levels twice a week for 2 weeks. There was a clear dose-dependent beneficial effect of this chaperone (Fig. 3C).

TUDCA-treated NOD mice preserved serum insulin at the level observed in vehicle-treated animals, which did not progress to diabetes (Fig. 3D) (Veh-D versus TUDCA, P < 0.0001 by Student’s t test). Histological analysis of pancreatic sections demonstrated noticeably reduced aggressive insulitis in TUDCA-treated mice compared with vehicle-treated diabetic (Veh-D) NOD mice (Fig. 3E). Furthermore, islets from mice receiving TUDCA remained largely intact despite the presence of
Fig. 1. Time-course detection of altered expression of UPR mediators in the islets of NOD mice. Female NOD mice (n = 14 for each group) were sacrificed at 3, 5, 7, 9, and 13 weeks of age. (A and B) Immunofluorescence assays were performed on the pancreatic sections by co-staining with either (A) anti-ATF6 antibody (red) or (B) anti-sXBP1 (red) and anti-insulin (green) antibodies. The cell nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) (blue). (C to E) Relative fluorescence intensity (RFI) for (C) ATF6, (D) sXBP1, and (E) insulin was calculated by MATLAB (15 to 25 islets per animal per time point). (F) Serum insulin levels of NOD mice (n = 14) were measured by enzyme-linked immunosorbent assay (ELISA). All data are presented as means ± SEM, with statistical analysis performed by one-way analysis of variance (ANOVA) (**P < 0.005; *P < 0.05).
Table 1. Information on the T1D and control nondiabetic donors. Pancreatic sections were obtained from nPOD for immunofluorescence analysis of UPR mediators. Ins, insulin; Gluc, glucagon; Ab, antibody; N/A, not applicable.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Ethnicity</th>
<th>Duration of diabetes (years)</th>
<th>AutoAb</th>
<th>Histology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ctrl 0.5</td>
<td>Female</td>
<td>African American</td>
<td>N/A</td>
<td>Negative</td>
<td>Normal islet</td>
<td></td>
</tr>
<tr>
<td>Ctrl 2.9</td>
<td>Male</td>
<td>African American</td>
<td>N/A</td>
<td>Negative</td>
<td>Normal islet</td>
<td></td>
</tr>
<tr>
<td>Ctrl 17.8</td>
<td>Male</td>
<td>Caucasian</td>
<td>N/A</td>
<td>Negative</td>
<td>Normal islet, few with vascular stasis</td>
<td></td>
</tr>
<tr>
<td>Ctrl 19.2</td>
<td>Male</td>
<td>Caucasian</td>
<td>N/A</td>
<td>Negative</td>
<td>Normal islet</td>
<td></td>
</tr>
<tr>
<td>Ctrl 32</td>
<td>Female</td>
<td>Caucasian</td>
<td>N/A</td>
<td>Negative</td>
<td>Normal islet, low Ki67</td>
<td></td>
</tr>
<tr>
<td>Ctrl 59</td>
<td>Female</td>
<td>Caucasian</td>
<td>N/A</td>
<td>Negative</td>
<td>Normal islet</td>
<td></td>
</tr>
<tr>
<td>T1D 13.1</td>
<td>Female</td>
<td>Caucasian</td>
<td>1</td>
<td>mIAA+</td>
<td>Ins+ (reduced)/Gluc+ islets; insulitis</td>
<td></td>
</tr>
<tr>
<td>T1D 33.9</td>
<td>Female</td>
<td>Caucasian</td>
<td>4</td>
<td>Negative</td>
<td>Ins+/Gluc+ islets; increased acinar Ki67</td>
<td></td>
</tr>
<tr>
<td>T1D 14.2</td>
<td>Male</td>
<td>Caucasian</td>
<td>4</td>
<td>mIAA+</td>
<td>Ins+ islets in lobules with moderate to severe adipose infiltrates</td>
<td></td>
</tr>
<tr>
<td>T1D 31.2</td>
<td>Male</td>
<td>Caucasian</td>
<td>5</td>
<td>GADA+, IA2A+, ZnT8A+, mIAA+</td>
<td>Ins+ islets (much decreased); insulinis; chronic pancreatitis</td>
<td></td>
</tr>
<tr>
<td>T1D 22.8</td>
<td>Female</td>
<td>Caucasian</td>
<td>7</td>
<td>IA-2A+, mIAA+</td>
<td>Ins+ islet (few); occ. Ki67+ islet cell; insulinitis</td>
<td></td>
</tr>
<tr>
<td>T1D 22.9</td>
<td>Male</td>
<td>African American</td>
<td>7</td>
<td>No serum available</td>
<td>Ins+ islet of various sizes; acinar atrophy and fibrosis</td>
<td></td>
</tr>
<tr>
<td>T1D 18.8</td>
<td>Female</td>
<td>Caucasian</td>
<td>8</td>
<td>IA-2A+, ZnT8A-</td>
<td>Ins+ islet in occ. lobule, Ins+ islet</td>
<td></td>
</tr>
<tr>
<td>T1D 20.3</td>
<td>Male</td>
<td>Caucasian</td>
<td>13</td>
<td>mIAA+</td>
<td>Ins+ (very reduced)/Gluc+ variable within lobules, islet atrophy</td>
<td></td>
</tr>
<tr>
<td>T1D 31.4</td>
<td>Male</td>
<td>Hispanic</td>
<td>15</td>
<td>Negative</td>
<td>Ins+ islet; mild to moderate chronic pancreatitis</td>
<td></td>
</tr>
<tr>
<td>T1D 50</td>
<td>Female</td>
<td>Caucasian</td>
<td>20</td>
<td>mIAA+</td>
<td>Ins+ islet, insulinis, Ins+ Gluc+ islets</td>
<td></td>
</tr>
</tbody>
</table>

inflammatory cells in both the NOD and RIP-LCMV-GP models (Fig. 3, E and F). These results indicate that treatment with TUDCA renders the β cells of diabetes-prone mice significantly more resistant to aggressive immune cell infiltration than those of untreated animals. This is reflected in increased serum insulin, markedly preserved islet architecture, and reduced diabetes incidence.

It is possible that systemic administration of TUDCA could lead to alterations in immune phenotype through its antiapoptotic effects or other unknown mechanisms. To address this issue, we treated 10-week-old, normoglycemic female NOD mice with either phosphate-buffered saline (PBS) (vehicle) or TUDCA (500 mg/kg per day) for 4 weeks and collected the spleen, pancreas, and pancreatic lymph nodes for immunophenotyping via flow cytometry. T1D is a T cell–dominated autoimmune disease, although various types of other immune cells, including B and myeloid cells, are also involved (41). CD4+CD25+Foxp3+ T regulatory cells (Tregs) play an important role in controlling diabetes progression both in mouse models and in human T1D patients (42–44). TUDCA treatment did not cause alterations in the percentages of CD4+ or CD8+ T cells (Fig. 4, A to C), Tregs (Fig. 4, D and E), or B cells (Fig. 4, F and G) locally in the pancreas. There were also no differences in the corresponding cell populations in lymph nodes or spleens from TUDCA- versus vehicle-treated mice (figs. S4 and S5). Hence, systemic administration of TUDCA treatment did not affect the relative representation of immune cell populations critically implicated in T1D. On the other hand, TUDCA-treated NOD mice showed less severe islet infiltration by immune cells, suggesting that better islet function and survival led to less recruitment of immune cells to the islets, perhaps reflecting less antigen presentation.

In light of these data, we next focused on exploring the mechanisms underlying the beneficial effects of TUDCA. We first examined UPR markers in β cells for their potential alterations in 30-week-old vehicle- or TUDCA-treated animals. In both the RIP-LCMV-GP and NOD models, there was a striking loss of ATF6 expression in β cells upon emergence of diabetes compared with controls; this decrease in ATF6 expression was, to a great extent, maintained in TUDCA-treated animals in both models of disease (Fig. 5, A to D). This prompted us to investigate whether TUDCA could cause relevant molecular changes in normoglycemic mice before the onset of diabetes. For this purpose, we administered TUDCA for 4 weeks to 10-week-old NOD mice. Insulins scoring was performed on hematoxylin and eosin (H&E)–stained pancreatic step sections (n = 8 each group) to explore the extent of inflammation in the islets (Fig. 5E). Quantification revealed an increase in the percentage of islets without any insulitis in TUDCA-treated mice in comparison with pancreatic sections of vehicle (PBS)–treated animals (Fig. 5F). Furthermore, the number of islets with severe insulitis was significantly decreased in the TUDCA-treated group compared with controls (Fig. 5G). In addition to reducing ER stress in β cells, the decreased islet inflammatory cell infiltration mediated by TUDCA treatment diminished cell death, which resulted from decreased inflammatory insult; consistent with this notion, we detected a fivefold...
reduction in TUNEL (terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick-end labeling)–positive cells in the islets of the TUDCA-treated animals (n = 8, P < 0.001 by Student’s t test) (Fig. 5H). To investigate whether 4 weeks of TUDCA treatment altered the expression of UPR markers in prediabetic NOD mice, we grouped the pancreata from vehicle- and TUDCA-treated animals according to their insulitis scoring and stained the pancreatic sections with sXBP1 and ATF6 antibodies. Although the expression of these UPR mediators was substantially down-regulated in β cells of the vehicle-treated mice that exhibited a more aggressive inflammatory phenotype (Veh*), the expression of these markers in TUDCA-treated islets was indistinguishable from that in the vehicle-treated animals with a low degree of inflammation (Fig. 5, I to L). These data indicate that TUDCA preserves the expression of key UPR components in β cells, likely by increasing ER capacity and leading cells toward a prosurvival fate rather than a proapoptotic one.

We also examined whether TUDCA could affect β cell survival in vivo in the RIP-LCMV-GP model of T1D. TUNEL staining of pancreatic sections indicated a nearly fivefold decrease in islet cell death in TUDCA-treated RIP-LCMV-GP mice, compared with vehicle-treated animals, indicating that TUDCA treatment reduces apoptosis in β cells (Fig. 6A). We directly tested this possibility in a mouse insulin-producing cell line (Min6) to study the impact of TUDCA on prolonged ER stress–induced β cell death in vitro. Tunicamycin treatment of these cells induced death, as evidenced by significantly increased TUNEL positivity (Fig. 6B). This ER stress–induced increase in cell death was markedly reversed by TUDCA exposure (Fig. 6B). At the molecular level, the expression levels of p-JNK, CCAAT/enhancer-binding protein homologous protein (CHOP), cleaved poly(adenosine diphosphate–ribose) polymerase (PARP), and caspase-3 proteins were significantly increased upon tunicamycin treatment of Min6 cells, but these effects were reversed by TUDCA treatment (Fig. 6C). Local inflammatory cytokines produced...
by infiltrating lymphocytes may also contribute to ER stress or aggravate β cell apoptotic outcomes. To test this possibility, we treated Min6 cells with a cytokine cocktail (TNF-α + IFN-γ + IL-1β) alone or together with a chemical ER stress inducer, thapsigargin, and examined cell viability. Treatment of the cells with thapsigargin or the cytokine mixture caused a decrease in cell viability (Fig. 6, D and E). Further treatment of the thapsigargin-treated cells with TUDCA resulted in a small but significant decrease in cell viability (Fig. 6, D and E). Further treatment of the thapsigargin-treated cells with TUDCA resulted in a small but significant decrease in cell viability (Fig. 6, D and E).

We next used a molecular approach to modulate adaptive ER responses and study the impact on β cell survival and function. We focused on ATF6 manipulation because this branch of the UPR is markedly suppressed in β cells in disease models (as shown in Figs. 1A and 5C). For this purpose, Min6 cells were stably transduced with a lentiviral construct in which the expression of the ATF6 was under the control of doxycycline. In this system, thapsigargin or cytokine treatment resulted in a significant decrease in cell viability and an increase in the expression of the proapoptotic transcription factors CHOP and caspase-3. This increase was partially reversed upon doxycycline-induced ATF6 expression (Fig. 6, F to H). We also tested whether higher levels of ATF6 potentiated TUDCA’s ability to protect Min6 cells against death. There was a statistically significant increase in cell viability in ATF6-expressing cells (Fig. 6I), although this was of small magnitude (15 versus 23%) at the dose of TUDCA tested (30 µM). TUDCA treatment restored insulin secretion to a significantly greater extent in ATF6-overexpressing Min6 cells exposed to thapsigargin (Fig. 6J). At this low dose, however, TUDCA failed to protect wild-type Min6 cells against thapsigargin-induced decrease in insulin secretion under low- and high-glucose conditions (Fig. 6J). On the other hand, TUDCA significantly restored glucose-induced insulin secretion (GSIS) in cells expressing exogenous ATF6 (Fig. 6J). These results suggest that ATF6 expression is critical for the beneficial effects of TUDCA on cell viability and insulin secretion in β cells.

Fig. 3. Decreased diabetes incidence in NOD and RIP-LCMV-GP mice upon treatment with TUDCA. (A) Female NOD mice (n = 20 in each group) received twice-daily intraperitoneal injections of TUDCA (250 mg/kg) or vehicle (PBS) starting at 10 weeks of age, and blood glucose levels were monitored up to 30 weeks of age. (B) The same treatment was applied to RIP-LCMV-GP mice (n = 12) right after induction of diabetes with LCMV [2 × 10^5 plaque-forming units (PFU)/ml] and blood glucose levels were monitored for 2 weeks. (C) Reduction of diabetes incidence with various doses of TUDCA in RIP-LCMV-GP animals was determined after 2 weeks of treatment. (D) Serum insulin levels were measured by ELISA in vehicle (PBS)–treated NOD mice without diabetes (Veh-ND), vehicle-treated NOD mice with diabetes (Veh-D), or TUDCA-treated NOD mice (TUDCA). (E) Pancreatic sections from vehicle (PBS)– or TUDCA-treated NOD mice (30 weeks of age) were stained with H&E. Representative images of vehicle-treated mice without diabetes (Veh-ND) are presented in the upper panel. TUDCA treatment restored insulin secretion to a significantly greater extent in ATF6-overexpressing Min6 cells exposed to thapsigargin (Fig. 6J). At this low dose, however, TUDCA failed to protect wild-type Min6 cells against thapsigargin-induced decrease in insulin secretion under low- and high-glucose conditions (Fig. 6J). On the other hand, TUDCA significantly restored glucose-induced insulin secretion (GSIS) in cells expressing exogenous ATF6 (Fig. 6J). These results suggest that ATF6 expression is critical for the beneficial effects of TUDCA on cell viability and insulin secretion in β cells.
We reasoned that if TUDCA is acting through ATF6 to generate its protective effects against T1D, it should fail to exhibit these activities in the absence of ATF6 in vivo. To test this hypothesis, we produced a mouse model of ATF6 deficiency in β cells (Fig. 7A) using a tamoxifen-inducible, Cre-mediated recombination system driven by the rat insulin 2 promoter, and demonstrated specific loss of ATF6 in β cells using immunofluorescence (Fig. 7, B and C). We crossed these animals into the C57BL/6J genetic background and with the RIP-LCMV-GP mice (ATF6-β–deficient mice). Mice with heterozygous or homozygous ATF6 deletions in β cells developed normally and showed body weights similar to those of their respective controls (fig. S6A). The semi were slightly more insulin-sensitive and exhibited a lower insulin secretion curve in the GSIS assay (fig. S6, B to D).

To determine whether TUDCA’s antiapoptotic effects on β cells were altered in the absence of ATF6, we isolated pancreatic islets from wild-type and ATF6-β–deficient mice and treated the islets in culture with thapsigargin in the presence or absence of TUDCA (fig. S6E). Although TUDCA significantly protected wild-type islets from apoptosis, it failed to show any preventive activity against the already increased death in ATF6-deficient primary islets (fig. S6E). These data suggest that the antiapoptotic effects of TUDCA in β cells require ATF6.

Finally, we asked whether this mechanism is also in place in the context of an in vivo model of T1D. For this, we induced diabetes in β cell–specific ATF6α-deficient mice and ATF6 wild-type controls that had been crossed with the RIP-LCMV-GP transgenic model by LCMV administration in the presence or absence of TUDCA treatment (Fig. 7D). In the vehicle-treated controls, there was no difference in the incidence of LCMV-induced diabetes between the ATF6α-deficient and ATF6 wild-type control mice (Fig. 7D). However, although TUDCA treatment significantly reduced diabetes incidence in mice with intact ATF6 (66 versus 100%), its protective effects were completely lost in mice with β cell–specific ATF6α deficiency (Fig. 7D). In wild-type mice, TUDCA treatment resulted in significantly increased β cell insulin staining intensity (Fig. 7E), higher sXBP1 protein levels (Fig. 7F),
Fig. 5. Recovery of adaptive UPR mediators in islets of TUDCA-treated NOD and RIP-LCMV-GP mice. (A) Pancreatic sections from 30-week-old vehicle-treated nondiabetic (Veh-ND) \((n = 5)\), vehicle-treated diabetic (Veh-D) \((n = 4)\), and TUDCA-treated \((n = 9)\) NOD mice stained with anti-ATF6 (red) and anti-insulin (green). The cell nuclei were counterstained with DAPI (blue). (B) Quantification of relative fluorescence intensity (RFI) of insulin and ATF6 in the islets of vehicle-treated nondiabetic (Veh-ND), vehicle-treated diabetic (Veh-D), and TUDCA-treated NOD mice. (C) Pancreatic sections from 16-week-old vehicle-treated diabetic (upper panel) or TUDCA-treated RIP-LCMV-GP (lower panel) mice stained with anti-ATF6 (red) and anti-insulin (green). The cell nuclei were counterstained with DAPI (blue). (D) Quantification of islet fluorescence intensity of insulin and ATF6 in vehicle- and TUDCA-treated mice. (E) Insulitis scoring was performed on the H&E-stained step sections of the pancreata from 10-week-old NOD mice treated with either PBS vehicle \((n = 8)\) or TUDCA \((n = 8)\) for 4 weeks. (F) Vehicle- or TUDCA-treated NOD mouse islets were quantified for the presence of insulitis \((P < 0.05)\). (G) Vehicle- or TUDCA-treated NOD mouse islets were quantified for the presence of the islets that displayed aggressive insulitis. TUDCA-treated mice had significantly lower percentages of islets with aggressive insulitis. (H) Pancrea from control and TUDCA-treated animals were assessed for apoptosis with the TUNEL assay. (I and K) Vehicle- and TUDCA-treated normoglycemic NOD mouse pancreata were costained with (I) anti-ATF6 (red) or (K) anti-sXBP1 (red) and anti-insulin (green) antibodies. Vehicle-treated animals were grouped according to their insulitis scoring [determined in (E)], and the group with the lowest insulitis scoring is shown in the upper panel. Vehicle-treated animals with severe insulitis were indicated as Veh* (middle panel). The staining of TUDCA-treated animals is shown in the lower panel. Relative fluorescence intensity analysis indicated significantly reduced (J) ATF6 and (L) sXBP1 expression in the group with higher insulitis scoring, whereas TUDCA-treated animals showed a similar degree of expression to the animals with lower insulitis scoring. Insulin expression in the islets was the same in all groups (J and L). Data are presented as means ± SEM, with statistical analysis performed by one-way ANOVA (B, J, and L) or by Student's t test (D and F to H) \((**P < 0.01; *P < 0.05)\).
TUDCA-driven protection of β cells against cytokine- and ER stress–induced cell death. (A) Pancreatic sections from vehicle- or TUDCA-treated RIP-LCMV-GP mice were assessed for apoptosis with the TUNEL assay. White arrowheads indicate TUNEL-positive cells. (B) Min6 cells were treated with tunicamycin (1 μg/ml) for 18 hours with or without TUDCA, and cell death was determined with the TUNEL assay. (C) Min6 cells were treated as in (B), and markers of apoptosis were analyzed by Western blotting with anti–p-JNK, anti-CHOP, anti–cleaved PARP, and anti–caspase-3 antibodies. (D) Min6 cells were treated with 1 μM thapsigargin with or without 250 μM TUDCA for 24 hours. Cell viability was assessed with the XTT assay (sodium 3′-[(1-phenyl amino-carbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzene sulfonic acid hydrate) assay. (E) Min6 cells were treated with a cytokine cocktail with or without 250 μM TUDCA for 40 hours. Cell viability was assessed with the XTT assay. (F) Min6 cells transduced with a lentivirus expressing 3XFlag-tagged ATF6. After treatment of Min6 cells with 3 μM doxycycline for 24 hours, 1 μM thapsigargin was added to the medium for 24 hours, and cell viability was determined with the XTT assay. (G) Transduced Min6 cells were treated with 3 μM doxycycline for 24 hours, the cytokine cocktail was added to the medium for 24 hours, and cell viability was determined with the XTT assay. (H) Transduced Min6 cells were treated with 3 μM doxycycline for 24 hours, 1 μM thapsigargin was added to the medium, and incubation was continued for an additional 24 hours. Apoptosis markers were analyzed by Western blotting with anti–CHOP and anti–caspase-3 antibodies. (I) Transduced Min6 cells were treated with either vehicle or 0.1 μM thapsigargin for 24 hours. Thapsigargin (1 μM) was added to the medium, incubation was continued for an additional 24 hours in the presence or absence of 30 μM TUDCA, and then cell viability was determined with the XTT assay. (J) Cultured Min6 cells were transduced with a lentivirus expressing 3XFlag-tagged ATF6 and then treated with either vehicle or 3 μM doxycycline for 24 hours. Thapsigargin (1 μM) was then added to the medium, incubation was continued for an additional 24 hours in the presence or absence of 50 μM TUDCA, and GSIS under low- and high-glucose conditions was determined by insulin ELISA. Results were replicated in three independent experiments. Data are presented as means ± SEM, with statistical analysis performed by Student’s t test (A, B, and D to G) or one-way ANOVA (I and J) (**P < 0.001; *P < 0.05).
Fig. 7. TUDCA protection of β cells through the ATF6 branch of the UPR. (A) Schematic representation of a targeting vector used for the generation of conditional β cell–specific ATF6-deficient (ATF6<sup>−/−</sup>) mice. (B) Genotyping of control and ATF6<sup>−/−</sup> mice was performed with tail DNA. (C) An immunofluorescence assay was performed to validate the tissue-specific deletion of ATF6. (D) Vehicle (PBS) or TUDCA (250 mg/kg twice daily via intraperitoneal injection) was applied to ATF6 wild-type (wt) control mice or ATF6<sup>−/−</sup> RIP-LCMV-GP mice immediately after induction of diabetes with LCMV (2 × 10<sup>3</sup> PFU/ml), and blood glucose levels were monitored for 2 weeks. (E) Female control and ATF6<sup>−/−</sup>; RIP-LCMV-GP; Ins2Cre mice were treated with either vehicle or TUDCA (n = 4 each group) for 2 weeks. (F) The mice were then sacrificed, and the relative immunofluorescence intensity (RFI) of insulin (green) or sXBP1 (red) expression (20 to 30 islets per animal per group) was quantified by MATLAB. (G) Pancreatic sections from vehicle- or TUDCA-treated control and ATF6<sup>−/−</sup> RIP-LCMV-GP mice (n = 4 each group, 20 to 30 islets per group) were examined for apoptosis with the TUNEL assay. All data are presented as means ± SEM, with statistical analysis performed by one-way ANOVA (**P < 0.001; ***P < 0.005; *P < 0.05).

and a lower number of apoptotic cells (Fig. 7G). All of these restorative TUDCA activities were absent from the islets of β cell–specific ATF6-deficient mice (Fig. 7, E to G). Together, these data demonstrate that TUDCA protects β cells against ER stress–induced death as well as against in vivo development of immune-mediated diabetes in an ATF6-dependent manner.

**DISCUSSION**

There is increasing evidence in T1D that stress mechanisms intrinsic to β cells are critical for the demise of these cells in the presence of autoimmunity (4). This property is also evidenced by the limited long-term utility of immunosuppressive therapeutic strategies in T1D (45). Therefore, a mechanistic understanding of β cell–specific stress mechanisms and the development of therapeutic tools to target these pathways carry important translational implications.

In recent years, ER stress and related signaling networks have been implicated in the survival of β cells. For example, recent findings indicate that markers of the UPR are expressed in inflamed islets of both diabetes-prone NOD mice (30) and patients with T1D (31). However, it remains to be determined whether ER stress contributes to the pathogenesis of T1D or is an epiphenomenon of the local inflammation and mechanisms that determine the outcome of the UPR during insulitis. It is also unclear whether the ER can be targeted for the prevention and treatment of T1D in experimental models and in humans.
Here, we demonstrate a progressive loss of UPR mediator expression before the onset of diabetes in NOD mice. Two key transcriptional regulators of adaptive UPR, sXBP1 and ATF6, were severely diminished in β cells at the onset of diabetes in NOD and RIP-LCMV transgenic mice. The third canonical branch of the UPR regulated by PERK showed an initial up-regulation (as assessed by the expression of phospho-eIF2α) followed by stability in non-β cells of the islets of both mouse models of T1D. UPR indicators ATF6 and sXBP1 were similarly down-regulated in pancreatic sections of T1D humans. Hence, deficiency of these UPR branches involved in relevant cell-adaptive mechanisms correlates with β cell death and insulin deficiency in both experimental models and human T1D. These findings suggest that mitigation of ER stress, increase in ER capacity, and promotion of pro-survival outcomes of the UPR might be important for maintaining β cell homeostasis and survival when under an autoimmune attack. Consistent with this hypothesis, our results indicate that TUDCA, a molecule that modulates the UPR, significantly reduced the incidence of diabetes, improved insulin secretion and β cell morphology, and hindered the autoimmune attack of pancreatic islets in mouse models of T1D when applied at the pre-diabetic stage. In addition, administration of TUDCA prevented the loss of expression of the critical UPR regulators ATF6 and XBP1.

Our histological studies indicate that highly secretory β cells need an active and well-balanced UPR to function properly, especially when faced with proinflammatory signals that may lead to ER stress. The UPR is a dynamic cellular response integrated to inflammatory cues, and when key adaptive mechanisms fail, the UPR provides signals that may cause a shift from a compensatory to an apoptotic outcome (32). Consistent with this notion, islets from alloxan-induced diabetes-resistant (ALR/LT) mice, whose genomes show 70% homology to the NOD genome but are resistant to autoimmune destruction (46, 47), have increased expression of molecules critical for adapting to ER stress, including heat shock proteins, glucose-regulated protein 94 (GRP94), GRP78, protein disulfide isomerase, and calreticulin (47). To date, various branches of the UPR have been implicated in β cell biology and pathology. For example, a loss-of-function mutation in Pem causes permanent neonatal diabetes (Wolcott-Rallison syndrome) in humans and mice (9, 11). Another mediator of the UPR, IRE1, is required for insulin biosynthesis in vitro and in vivo (15). However, the function and significance of the third branch of the UPR, namely, the ATF6 axis, in diabetes remains largely unknown. As discussed above, prolonged ER stress can cause a switch from adaptive to pro-apoptotic UPR, and defective UPR activity during chronic stress may serve as a critical point for cells to switch from homeostasis to malfunction and apoptosis (48, 49). During prolonged ER stress, ATF6 expression decreases in some human cells, suggesting that attenuated ATF6 signaling creates an imbalance between pro-apoptotic and adaptive outcomes (49). In line with this interpretation, inhibition of ATF6 through a proteinase inhibitor or via a dominant-negative mutant of ATF6 impairs cardiac function in mice (50), whereas mice that express a constitutively active version of ATF6 have improved cardiac function after myocardial infarction compared with wild-type littermates (50). This beneficial effect of ATF6 was confirmed in ischemia and reperfusion animal models (51). A similar loss of ATF6 activity has been observed in the liver of obese and T2D animal models, leading to dysregulated hepatic glucose production (52).

In β cells, suppression of ATF6 expression decreases viability even in the absence of ER stress (53). Our findings suggest that in pathophysiological conditions characterized by chronic ER stress, diminished ATF6 or sXBP1 activity inhibits adaptive responses in favor of cell death. If this hypothesis is correct, appropriate complementation of the diminished branches of UPR activity may restore homeostasis, a postulate that has remained untested in β cells in vivo. Our observations demonstrated markedly diminished ATF6 activity in β cells of mice and humans with T1D. However, immunostaining results in human cadaver samples must be viewed with caution because the small sample number presents limitations in making precise comparisons, and samples can exhibit variations as a result of the procurement strategy.

To investigate the impact of decreased ATF6 expression and the role of the corresponding UPR branch in mediating chemical chaperone activity, we generated an inducible model of ATF6 deficiency in β cells. Consistent with previous in vitro findings, deletion of the ATF6 in β cells of RIP-LCMV-GP mice increased the rate of β cell apoptosis as studied in isolated islets (fig. S6E). Although TUDCA was effective in protecting against ER stress—induced death and loss of function in cultured β cell systems, no such protective effect was evident in β cells that lacked ATF6. Heterozygous or homozygous deletion of ATF6 from β cells did not alter glucose homeostasis or β cell health, whereas β cell-specific deletion of ATF6 abrogated the protective effects of TUDCA against T1D in the RIP-LCMV model. These in vitro and in vivo observations demonstrate that TUDCA improves β cell survival in the context of an immune attack, at least in part by restoring ATF6. In addition to the important implications for T1D, our findings also provide a molecular mechanism underlying TUDCA action, which is ATF6-dependent in vitro and in vivo.

There are presently no effective regimens for prevention or etiologically oriented treatment of T1D (54, 55). Detection of multiple circulating islet autoantibodies can identify individuals at high risk for development of T1D (56, 57). This capability emphasizes the need for safe and effective approaches to decrease progressive β cell loss and prevent or delay clinical disease. Our data support the possibility that ER-modifying agents such as TUDCA might be used for this purpose in high-risk, autoantibody-positive individuals and perhaps in recently diagnosed T1D patients. TUDCA is an approved drug for human use in some cases of liver disease with no major side effects (58, 59). Administration of TUDCA and other chemical chaperones increases insulin sensitivity in obese humans and in rodent models of T2D (39, 40), suggesting that ER stress can be similarly ameliorated in both species. Finally, most existing therapeutic strategies against T1D involve targeting the immune response (45, 60). Our results support the notion of β cell preservation through the use of TUDCA or potentially other ER-modulating agents as an alternative translational strategy.

**MATERIALS AND METHODS**

**Study design**

The overall objective of this project was to study β cell ER stress and the UPR in the context of autoimmune diabetes. To do this, we examined the expression patterns of molecules critical in the UPR in the islets of NOD mice and human patients with T1D. We then treated two different T1D animal models with a chemical chaperone, TUDCA, to alleviate ER stress in these mice. We performed in vitro and in vivo analyses to get insight into the function of TUDCA in β
cell survival and function. Insulitis scoring and TUNEL assays were performed in a blinded manner with coded labels. In vitro experiments were repeated at least three times. Except in the study where NOD mice were treated with TUDCA for 20 weeks, in vivo experiments were also repeated at least three times.

**Mouse models**

The animal care and experimental procedures were performed with approval from the animal care committees of Harvard University. Female NOD/ShiLtJ mice were purchased from The Jackson Laboratory, kept on a 12-hour light cycle, and fed with regular diet. The RIP-LCMV-GP mice were a gift from K. Bornfeldt’s laboratory at Washington University in Seattle. ATF6 conditional knockout mice were generated with a targeting construct in which exons 8 and 9 of ATF6 were flanked by LoxP sequences. Ins2Cre mice, which have a tamoxifen-inducible Cre-mediated recombination system driven by the rat insulin 2 (Ins2) promoter, were purchased from The Jackson Laboratory. The genetic backgrounds of all intercrossed mouse models were verified by genotyping (288 loci for C57BL/6J) with an ABI 3730XL Genetic Analyzer. Ins2Cre mice were crossed with RipCre; Ins2Cre mice were determined by congenic genotyping (288 loci for C57BL/6J) with an ABI 3730XL analyzer. The genetic characteristics of all intercrossed mouse models were identical. Immunocytochemical staining was performed according to established protocols. The Promega DeadEnd Fluorometric TUNEL system was performed on formalin-fixed, paraffin-embedded pancreatic sections according to the manufacturer’s instructions. For cell viability assays, insulin-producing mouse Min6 cells (1 × 10⁶) were seeded in 96-well microculture plates and treated with various doses of thapsigargin, cytokines, and other indicated chemicals. The number of surviving cells was measured by the MTS assay (American Type Culture Collection) with a microplate reader. Min6 cells were cultured in Dulbecco’s modified Eagle’s medium supplemented with penicillin, streptomycin, and 5% FBS. Cells were maintained at 37°C in 5% CO₂ atmosphere and treated with tunicamycin (1 to 3 μg/ml), thapsigargin (1 μM; Sigma), TUDCA (50 or 500 μg/ml; CalBiochem), and the cytokines TNF-α, IL-1β, and IFN-γ at the indicated doses (PeproTech).

**Human pancreatic tissue**

Paraffin-embedded pancreatic sections from diabetes-free controls and T1D patients were obtained from the Juvenile Diabetes Research Foundation (JDRF)–sponsored nPOD program (http://www.jdrfnpod.org/online-pathology.php). Sections were used for staining and quantification of expression levels of selected UPR markers.

**Histological analyses**

Pancreata from chemical- and vehicle-treated NOD and RIP-LCMV-GP mice were formalin-fixed and paraffin-embedded. Then, 5-μm serial sections of the pancreata were generated, and staining was performed with antibodies against insulin (Linco), glucagon, and ATF6 (Santa Cruz Biotechnology); phospho-eIF2α (Biosource); sXBP1 (in house) and GRP78 (Cell Signaling); anti-CHOP (Santa Cruz Biotechnology); and Alexa Fluor 488 and Alexa Fluor 568 (Invitrogen) according to established protocols.

**Image analysis**

After staining, image analysis was performed by using a custom software developed in MATLAB (The MathWorks Inc.). Briefly, islet regions were identified as contiguous areas (connected pixels) of insulin staining (green channel) at or above a threshold intensity value optimized across multiple images. Mean fluorescence intensity for insulin (green channel) and for either sXBP1 or ATF6 (red channel) was calculated as the sum of intensities for all pixels divided by the number of pixels within the islet.

**Immunophenotyping**

Single-cell suspensions of the pancreata were prepared by collagenase digestion. Cells from pancreatic lymph nodes and spleen were prepared by physical dissociation. All stainings were started by incubating with the anti–Fcγ receptor monoclonal antibody 2.4G2. Antibodies used for subsequent stainings were anti-CD45 (30-F11) and anti-Ly6C (AL-21) (BD Pharmingen), and anti-CD3 (145-2C11), anti-CD4 (RM4-5), anti-CD8 (53-6.7), anti-CD25 (PC61), anti-CD11b (M1/70), anti-CD11c (N418), anti-F4/80 (BM8), and anti-Gr1 (RB6-8C5) (all from BioLegend). Intracellular Foxp3 (FJK-16s) staining was performed according to eBioscience’s protocol. Samples were acquired with an LSR II (BD Biosciences), and data were analyzed with FlowJo software (Tree Star Inc.).

**Cell death (TUNEL) and viability (XTT) assays and insulin measurements**

Serum insulin levels were measured with the Alpco ELISA kit according to the manufacturer’s protocol. The Promega DeadEnd Fluorometric TUNEL system was performed on formalin-fixed, paraffin-embedded pancreatic sections according to the manufacturer’s instructions. For cell viability assays, insulin-producing mouse Min6 cells (1 × 10⁶) were seeded in 96-well microculture plates and treated with various doses of thapsigargin, cytokines, and other indicated chemicals. The number of surviving cells was measured by the XTT assay (American Type Culture Collection) with a microplate reader. Min6 cells were cultured in Dulbecco’s modified Eagle’s medium supplemented with penicillin, streptomycin, and 5% FBS. Cells were maintained at 37°C in 5% CO₂ atmosphere and treated with tunicamycin (1 to 3 μg/ml), thapsigargin (1 μM; Sigma), TUDCA (50 or 500 μg/ml; CalBiochem), and the cytokines TNF-α, IL-1β, and IFN-γ at the indicated doses (PeproTech).

**Islet isolation**

Islets were isolated by the Islet Resource Center at the Joslin Diabetes Center with the standard collagenase/protease digestion method. Briefly, the pancreatic duct was cannulated and distended with 4°C collagenase/protease solution with Liberase HI (Roche Diagnostics). Islets were separated from the exocrine tissue by continuous density-gradient centrifugation. Handpicked islets were cultured and counted before the experiments.

**Insulin secretion assay**

Min6 cells were cultured in six-well plates at 80% confluence, the growth medium was removed, and the cells were washed twice with PBS. Cells were preincubated for 30 min in 5% CO₂ at 37°C in Krebs-Ringer bicarbonate Hepes (KRH) buffer without glucose. Incubation medium was removed, and the cells were washed once in glucose-free KRH buffer and then incubated for 1 hour in KRH buffer containing the indicated treatment. Incubation medium was collected, and the amount of secreted insulin was determined with ELISA (Alpco, Ultra-sensitive Mouse Insulin ELISA) and normalized to the total protein concentration.

**Statistical analyses**

Analysis of data was performed with the GraphPad Prism program (GraphPad Software), and statistical tests were calculated by the Kaplan-Meier estimate. Data are presented as means ± SEM or SD and analyzed with the statistical tests indicated in the text and figure legends. P < 0.05 was considered statistically significant.

**Glucose and insulin tolerance tests and in vivo GSIS assay**

Glucose tolerance tests were performed in overnight fasted mice. Mice were given glucose (2 g/kg) intraperitoneally, and then blood glucose
levels were measured. Insulin tolerance tests were performed after a 6-hour daytime food withdrawal by intraperitoneal administration of recombinant human regular insulin (0.5 U/kg; Eli Lilly). In vivo GSIS tests were performed in mice after an overnight fast and by administration of glucose (2 g/kg). Serum insulin levels were quantified by ELISA (Alpco, Ultra sensitive Mouse Insulin ELISA).

**SUPPLEMENTARY MATERIALS**

www.sciencetranslationalmedicine.org/cgi/content/full/5/211ra156/DC1

Materials and Methods

Fig. S1. Specific alterations of the UPR mediators in the islets of NOD mice. Fig. S2. Specific alterations of Glu2 and Kae1 expression in the islets of NOD mice. Fig. S3. Dysregulation of the molecules critical in the UPR in the islets of male T1D patients. Fig. S4. Immunophenotyping of splenocytes of NOD mice after TUDCA treatment. Fig. S5. Immunophenotyping of pancreatic lymph nodes of NOD mice after TUDCA treatment. Fig. S6. Deletion of ATF6 branch of the UPR in β cells in vivo.

**REFERENCES AND NOTES**


Funding: This study was supported by a grant from JDRF to G.S.H. (17-2008-901). D.M. was supported by a grant from NIH PO1 (AI054904). D.L.E. was supported by grants from the European Union (Collaborative Projects Naimit and BetaBas in the Framework Program 7) and the Fonds National de la Recherche Scientifique. W.F. was supported by Schuyler funds. Author contributions: F.E. designed and performed all in vitro and in vivo experiments, established staining protocols for both human and mouse samples, analyzed the data, and helped write the manuscript. A.Y. and T.N. contributed to in vivo experiments and immunostainings. S.H. generated ATF6-targeting vector. W.F. helped with immunophenotyping of the mice. D.L.E. supervised the in vitro studies and edited the manuscript. D.M. supervised the immunological analyses and edited the manuscript. G.S.H. supervised the in vivo and in vitro studies and statistical analyses, analyzed the data, and wrote the manuscript. Competing interests: The authors declare that they have no competing interests.

Submitted 8 May 2013
Accepted 28 August 2013
Published 13 November 2013
10.1126/scitranslmed.3006534